REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
2. Dawson S, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. EJC 2009;45:27-40.
3. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
4. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
5. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
6. Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One 2016;11:e0157368.
8. Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N Engl J Med 2020;383:2557-70.
9. Elster N, Collins DM, Toomey S, Crown J, Eustace AJ, Hennessy BT. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer. Breast Cancer Res Treat 2015;149:5-15.
10. Reddy KB. Triple-negative breast cancers: an updated review on treatment options. Curr Oncol 2011;18:e173-9.
11. McCann KE, Hurvitz SA, McAndrew N. Advances in targeted therapies for triple-negative breast cancer. Drugs 2019;79:1217-30.
12. Lynce F, Nunes R. Role of platinums in triple-negative breast cancer. Curr Oncol Rep 2021;23:50.
13. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018;379:753-63.
14. Tutt ANJ, Garber JE, Kaufman B, et al. OlympiA clinical trial steering committee and investigators. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021;384:2394-405.
15. Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 2018;25:S142-50.
16. Schmid P, Adams S, Rugo HS, et al. IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379:2108-21.
17. Bardia A, Hurvitz SA, Tolaney SM, et al. ASCENT clinical trial investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 2021;384:1529-41.
18. Monteith GR, Prevarskaya N, Roberts-Thomson SJ. The calcium-cancer signalling nexus. Nat Rev Cancer 2017;17:367-80.
20. Stewart TA, Yapa KT, Monteith GR. Altered calcium signaling in cancer cells. Biochim Biophys Acta 2015;1848:2502-11.
21. Smedler E, Uhlén P. Frequency decoding of calcium oscillations. Biochim Biophys Acta 2014;1840:964-9.
22. Marchi S, Pinton P. Alterations of calcium homeostasis in cancer cells. Curr Opin Pharmacol 2016;29:1-6.
23. Bittremieux M, Parys JB, Pinton P, Bultynck G. ER functions of oncogenes and tumor suppressors: modulators of intracellular Ca2+ signaling. Biochim Biophys Acta 2016;1863:1364-78.
24. So CL, Saunus JM, Roberts-Thomson SJ, Monteith GR. Calcium signalling and breast cancer. Semin Cell Dev Biol 2019;94:74-83.
25. Monteith GR, Davis FM, Roberts-Thomson SJ. Calcium channels and pumps in cancer: changes and consequences. J Biol Chem 2012;287:31666-73.
26. Raynal NJ, Lee JT, Wang Y, et al. Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer. Cancer Res 2016;76:1494-505.
27. Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta Pharm Sin B 2017;7:3-17.
28. Bong AHL, Monteith GR. Calcium signaling and the therapeutic targeting of cancer cells. Biochim Biophys Acta Mol Cell Res 2018;1865:1786-94.
29. Catterall W. Calcium Channels. Encyclopedia of neuroscience. Elsevier; 2009. pp. 543-50.
30. Bagur R, Hajnóczky G. Intracellular Ca2+ sensing: its role in calcium homeostasis and signaling. Mol Cell 2017;66:780-8.
31. Varghese E, Samuel SM, Sadiq Z, et al. Anti-cancer agents in proliferation and cell death: the calcium connection. IJMS 2019;20:3017.
32. Foskett JK, White C, Cheung KH, Mak DO. Inositol trisphosphate receptor Ca2+ release channels. Physiol Rev 2007;87:593-658.
33. Berridge MJ. Inositol trisphosphate and diacylglycerol: two interacting second messengers. Annu Rev Biochem 1987;56:159-93.
34. Endo M, Tanaka M, Ogawa Y. Calcium induced release of calcium from the sarcoplasmic reticulum of skinned skeletal muscle fibres. Nature 1970;228:34-6.
35. Liou J, Kim ML, Heo WD, et al. STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx. Curr Biol 2005;15:1235-41.
36. Salido GM, Sage SO, Rosado JA. TRPC channels and store-operated Ca2+ entry. Biochim Biophys Acta 2009;1793:223-30.
37. Worley PF, Zeng W, Huang GN, et al. TRPC channels as STIM1-regulated store-operated channels. Cell Calcium 2007;42:205-11.
38. Pla A, Kondratska K, Prevarskaya N. STIM and ORAI proteins: crucial roles in hallmarks of cancer. Am J Physiol Cell Physiol 2016;310:C509-19.
39. Buchanan PJ, McCloskey KD. CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer therapeutics. Eur Biophys J 2016;45:621-33.
41. O’Reilly D, Downing T, Kouba S, et al. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer. Cell Calcium 2022;103:102554.
42. Nielsen N, Lindemann O, Schwab A. TRP channels and STIM/ORAI proteins: sensors and effectors of cancer and stroma cell migration. Br J Pharmacol 2014;171:5524-40.
43. Tajada S, Villalobos C. Calcium permeable channels in cancer hallmarks. Front Pharmacol 2020;11:968.
44. Déliot N, Constantin B. Plasma membrane calcium channels in cancer: alterations and consequences for cell proliferation and migration. Biochim Biophys Acta 2015;1848:2512-22.
45. Roderick HL, Cook SJ. Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer 2008;8:361-75.
46. Makena MR, Rao R. Subtype specific targeting of calcium signaling in breast cancer. Cell Calcium 2020;85:102109.
47. McAndrew D, Grice DM, Peters AA, et al. ORAI1-mediated calcium influx in lactation and in breast cancer. Mol Cancer Ther 2011;10:448-60.
48. Yang Y, Jiang Z, Wang B, et al. Expression of STIM1 is associated with tumor aggressiveness and poor prognosis in breast cancer. Pathol Res Pract 2017;213:1043-7.
49. Motiani RK, Zhang X, Harmon KE, et al. Orai3 is an estrogen receptor α-regulated Ca2+ channel that promotes tumorigenesis. FASEB J 2013;27:63-75.
50. Chakraborty S, Ghosh S, Banerjee B, et al. Phemindole, a Synthetic Di-indole derivative maneuvers the store operated calcium entry (SOCE) to induce potent anti-carcinogenic activity in human triple negative breast cancer cells. Front Pharmacol 2016;7:114.
51. Azimi I, Milevskiy MJG, Kaemmerer E, et al. TRPC1 is a differential regulator of hypoxia-mediated events and Akt signalling in PTEN-deficient breast cancer cells. J Cell Sci 2017;130:2292-305.
52. Lu C, Ma Z, Cheng X, et al. Pathological role of ion channels and transporters in the development and progression of triple-negative breast cancer. Cancer Cell Int 2020;20:377.
53. Lehmann BD, Colaprico A, Silva TC, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun 2021;12:6276.
54. Chen X, Li J, Gray WH, et al. TNBCtype: A subtyping tool for triple-negative breast cancer. Cancer Inform 2012;11:CIN.S9983.
55. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
56. Liu H, Murphy CJ, Karreth FA, et al. Identifying and targeting sporadic oncogenic genetic aberrations in mouse models of triple-negative breast cancer. Cancer Discov 2018;8:354-69.
57. Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer 2017;83:258-65.
58. Liu J, Zhang C, Feng Z. Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim Biophys Sin (Shanghai) 2014;46:170-9.
59. Coradini D, Biganzoli E, Ardoino I, et al. p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy. Breast 2015;24:294-7.
60. Li JP, Zhang XM, Zhang Z, Zheng LH, Jindal S, Liu YJ. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma. Medicine (Baltimore) 2019;98:e15449.
61. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
62. Pan Y, Yuan Y, Liu G, Wei Y. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. PLoS One 2017;12:e0172324.
63. Biganzoli E, Coradini D, Ambrogi F, et al. p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. Jpn J Clin Oncol 2011;41:172-9.
64. Fournier MV, Goodwin EC, Chen J, Obenauer JC, Tannenbaum SH, Brufsky AM. A predictor of pathological complete response to neoadjuvant chemotherapy stratifies triple negative breast cancer patients with high risk of recurrence. Sci Rep 2019;9:14863.
66. Yue X, Zhao Y, Xu Y, Zheng M, Feng Z, Hu W. Mutant p53 in cancer: accumulation, gain-of-function, and therapy. J Mol Biol 2017;429:1595-606.
67. Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ 2018;25:154-60.
68. Klein K, Oualkacha K, Lafond MH, Bhatnagar S, Tonin PN, Greenwood CM. Gene coexpression analyses differentiate networks associated with diverse cancers harboring TP53 missense or null mutations. Front Genet 2016;7:137.
69. Bittremieux M, Bultynck G. p53 and Ca2+ signaling from the endoplasmic reticulum: partners in anti-cancer therapies. Oncoscience 2015;2:233-8.
70. Haupt S, Raghu D, Haupt Y. p53 calls upon CIA (Calcium Induced Apoptosis) to counter stress. Front Oncol 2015;5:57.
71. Bonora M, Pinton P. The mitochondrial permeability transition pore and cancer: molecular mechanisms involved in cell death. Front Oncol 2014;4:302.
72. Giorgi C, Bonora M, Sorrentino G, et al. p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+-dependent manner. Proc Natl Acad Sci U S A 2015;112:1779-84.
73. Nedeljković M, Damjanović A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells 2019;8:957.
74. Giorgi C, Bonora M, Missiroli S, et al. Intravital imaging reveals p53-dependent cancer cell death induced by phototherapy via calcium signaling. Oncotarget 2015;6:1435-45.
75. Rohacs T. Regulation of transient receptor potential channels by the phospholipase C pathway. Adv Biol Regul 2013;53:341-55.
76. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev 2007;87:165-217.
77. Gogna R, Madan E, Keppler B, Pati U. Gallium compound GaQ3-induced Ca2+ signalling triggers p53-dependent and -independent apoptosis in cancer cells: GaQ3 induces Ca2+ signalling and p53 activation. Br J Pharmacol 2012;166:617-36.
78. Madan E, Gogna R, Keppler B, Pati U. p53 increases intra-cellular calcium release by transcriptional regulation of calcium channel TRPC6 in GaQ3-treated cancer cells. PLoS One 2013;8:e71016.
79. Kischel P, Girault A, Rodat-Despoix L, et al. Ion channels: new actors playing in chemotherapeutic resistance. Cancers (Basel) 2019;11:376.
80. Hasna J, Hague F, Rodat-Despoix L, et al. Orai3 calcium channel and resistance to chemotherapy in breast cancer cells: the p53 connection. Cell Death Differ 2018;25:693-707.
81. Brickley DR, Agyeman AS, Kopp RF, et al. Serum- and glucocorticoid-induced protein kinase 1 (SGK1) is regulated by store-operated Ca2+ entry and mediates cytoprotection against necrotic cell death. J Biol Chem 2013;288:32708-19.
82. Gibadulinova A, Tothova V, Pastorek J, Pastorekova S. Transcriptional regulation and functional implication of S100P in cancer. Amino Acids 2011;41:885-92.
83. Cong Y, Cui Y, Wang S, et al. Calcium-binding protein S100P promotes tumor progression but enhances chemosensitivity in breast cancer. Front Oncol 2020;10:566302.
84. Arumugam T, Logsdon CD. S100P: a novel therapeutic target for cancer. Amino Acids 2011;41:893-9.
85. Komatsu M, Yoshimaru T, Matsuo T, et al. Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. Int J Oncol 2013;42:478-506.
86. Maierthaler M, Kriegsmann M, Peng C, et al. S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer. Exp Mol Pathol 2015;99:180-7.
87. Gibadulinova A, Pastorek M, Filipcik P, et al. Cancer-associated S100P protein binds and inactivates p53, permits therapy-induced senescence and supports chemoresistance. Oncotarget 2016;7:22508-22.
88. Duffy MJ, Crown J. Drugging “undruggable” genes for cancer treatment: are we making progress? Int J Cancer 2021;148:8-17.
89. Synnott NC, O'Connell D, Crown J, Duffy MJ. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells. Breast Cancer Res Treat 2020;179:47-56.
90. Sallman DA, DeZern AE, Garcia-Manero G, et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol 2021;39:1584-94.
92. Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol 2021;12:628690.
93. Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat 2018;169:397-406.
94. Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol 2019;30:1051-60.
95. Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 2010;17:901-11.
96. López-Knowles E, O'Toole SA, McNeil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010;126:1121-31.
97. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-9.
98. Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun 2016;7:11479.
99. Chen SMY, Li B, Nicklawsky AG, et al. Deletion of p53 and hyper-activation of PIK3CA in Keratin-15+ stem cells lead to the development of spontaneous squamous cell carcinoma. Int J Mol Sci 2020;21:6585.
100. Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell 2019;35:428-440.e5.
101. Chen L, Yang L, Yao L, et al. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nat Commun 2018;9:1357.
102. Shi X, Wang J, Lei Y, Cong C, Tan D, Zhou X. Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review). Mol Med Rep 2019;19:4529-35.
103. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 2014;4:64.
104. Showkat M, Beigh MA, Andrabi KI. mTOR Signaling in protein translation regulation: implications in cancer genesis and therapeutic interventions. Mol Biol Int 2014;2014:686984.
105. Harms KL, Chen X. The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ 2006;13:890-7.
106. Lee C, Kim JS, Waldman T. Activated PI3K signaling as an endogenous inducer of p53 in human cancer. Cell Cycle 2007;6:394-6.
107. Singh B, Reddy PG, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002;16:984-93.
108. Astanehe A, Arenillas D, Wasserman WW, et al. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci 2008;121:664-74.
109. Wen J, Huang YC, Xiu HH, Shan ZM, Xu KQ. Altered expression of stromal interaction molecule (STIM)-calcium release-activated calcium channel protein (ORAI) and inositol 1,4,5-trisphosphate receptors (IP3Rs) in cancer: will they become a new battlefield for oncotherapy? Chin J Cancer 2016;35:32.
110. Marchi S, Marinello M, Bononi A, et al. Selective modulation of subtype III IP3R by Akt regulates ER Ca2+ release and apoptosis. Cell Death Dis 2012;3:e304.
111. Marchi S, Rimessi A, Giorgi C, et al. Akt kinase reducing endoplasmic reticulum Ca2+ release protects cells from Ca2+-dependent apoptotic stimuli. Biochem Biophys Res Commun 2008;375:501-5.
112. Milella M, Falcone I, Conciatori F, et al. PTEN: multiple functions in human malignant tumors. Front Oncol 2015;5:24.
113. Beg S, Siraj AK, Prabhakaran S, et al. Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer. Breast Cancer Res Treat 2015;151:541-53.
114. Li S, Shen Y, Wang M, et al. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis. Oncotarget 2017;8:32043-54.
115. Bononi A, Bonora M, Marchi S, et al. Identification of PTEN at the ER and MAMs and its regulation of Ca2+ signaling and apoptosis in a protein phosphatase-dependent manner. Cell Death Differ 2013;20:1631-43.
116. Boehmerle W, Splittgerber U, Lazarus MB, et al. Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism. Proc Natl Acad Sci U S A 2006;103:18356-61.
117. Nguyen LD, Petri ET, Huynh LK, Ehrlich BE. Characterization of NCS1-InsP3R1 interaction and its functional significance. J Biol Chem 2019;294:18923-33.
118. Boehmerle W, Zhang K, Sivula M, et al. Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc Natl Acad Sci U S A 2007;104:11103-8.
119. Singh A, Chagtoo M, Tiwari S, et al. Inhibition of Inositol 1, 4, 5-Trisphosphate Receptor Induce Breast Cancer Cell Death Through Deregulated Autophagy and Cellular Bioenergetics. J Cell Biochem 2017;118:2333-46.
120. Leite MF, Thrower EC, Echevarria W, et al. Nuclear and cytosolic calcium are regulated independently. Proc Natl Acad Sci U S A 2003;100:2975-80.
121. Rodrigues MA, Gomes DA, Leite MF, et al. Nucleoplasmic calcium is required for cell proliferation. J Biol Chem 2007;282:17061-8.
122. Guimarães E, Machado R, Fonseca MC, et al. Inositol 1, 4, 5-trisphosphate-dependent nuclear calcium signals regulate angiogenesis and cell motility in triple negative breast cancer. PLoS One 2017;12:e0175041.
123. Han F, Li CF, Cai Z, et al. The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. Nat Commun 2018;9:4728.
124. Jardin I, Lopez JJ, Salido GM, Rosado JA. Store-operated Ca2+ entry in breast cancer cells: remodeling and functional role. Int J Mol Sci 2018;19:4053.
125. Bhattacharya A, Kumar J, Hermanson K, et al. The calcium channel proteins ORAI3 and STIM1 mediate TGF-β induced Snai1 expression. Oncotarget 2018;9:29468-83.
126. Davis FM, Azimi I, Faville RA, et al. Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene 2014;33:2307-16.
128. Stewart TA, Azimi I, Thompson EW, Roberts-Thomson SJ, Monteith GR. A role for calcium in the regulation of ATP-binding cassette, sub-family C, member 3 (ABCC3) gene expression in a model of epidermal growth factor-mediated breast cancer epithelial-mesenchymal transition. Biochem Biophys Res Commun 2015;458:509-14.
129. Bong AHL, Bassett JJ, Roberts-Thomson SJ, Monteith GR. Assessment of doxorubicin-induced remodeling of Ca2+ signaling and associated Ca2+ regulating proteins in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 2020;522:532-8.
130. Zhang P, Liu X, Li H, et al. TRPC5-induced autophagy promotes drug resistance in breast carcinoma via CaMKKβ/AMPKα/mTOR pathway. Sci Rep 2017;7:3158.
131. Garrido-Castro AC, Saura C, Barroso-Sousa R, et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res 2020;22:120.
132. Martín M, Chan A, Dirix L, et al. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). Ann Oncol 2017;28:313-20.
133. Schmid P, Abraham J, Chan S, et al. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. J Clin Oncol 2020;38:423-33.
134. Turner N, Dent RA, O'Shaughnessy J, et al. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat 2022;191:565-76.
135. Liang X, Zhang N, Pan H, Xie J, Han W. Development of store-operated calcium entry-targeted compounds in cancer. Front Pharmacol 2021;12:688244.
136. Vashisht A, Trebak M, Motiani RK. STIM and Orai proteins as novel targets for cancer therapy. a review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol 2015;309:C457-69.
137. Santos R, Ursu O, Gaulton A, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov 2017;16:19-34.
138. Rahman S, Rahman T. Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca2+ entry pathway. Sci Rep 2017;7:12881.
139. Gutiérrez LG, Hernández-Morales M, Núñez L, Villalobos C. Inhibition of polyamine biosynthesis reverses Ca2+ channel remodeling in colon cancer cells. Cancers (Basel) 2019;11:83.
140. Zhang X, Feng Y, Liu X, et al. Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer. J Cancer Res Clin Oncol 2019;145:1387-403.
141. Núñez L, Valero RA, Senovilla L, Sanz-Blasco S, García-Sancho J, Villalobos C. Cell proliferation depends on mitochondrial Ca2+ uptake: inhibition by salicylate. J Physiol 2006;571:57-73.
142. Wang JY, Sun J, Huang MY, et al. STIM1 overexpression promotes colorectal cancer progression, cell motility and COX-2 expression. Oncogene 2015;34:4358-67.
143. Li P, Rubaiy HN, Chen GL, et al. Mibefradil, a T-type Ca2+ channel blocker also blocks Orai channels by action at the extracellular surface. Br J Pharmacol 2019;176:3845-56.
144. Im J. COX-2 regulates the insulin-like growth factor i-induced potentiation of Zn2+-toxicity in primary cortical culture. Mol Pharmacol 2004;66:368-76.
145. Dobrydneva Y, Williams RL, Blackmore PF. Diethylstilbestrol and other nonsteroidal estrogens: novel class of store-operated calcium channel modulators. J Cardiovasc Pharmacol 2010;55:522-30.
146. Tian C, Du L, Zhou Y, Li M. Store-operated CRAC channel inhibitors: opportunities and challenges. Future Med Chem 2016;8:817-32.
147. Kang SS, Han KS, Ku BM, et al. Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Res 2010;70:1173-83.
